Dr. Matthew J. Ehrhardt

Claim this profile

St. Jude Children's Research Hospital

Studies Lymphoma
Studies Hodgkin's Lymphoma
2 reported clinical trials
17 drugs studied

Area of expertise

1Lymphoma
Matthew J. Ehrhardt has run 2 trials for Lymphoma. Some of their research focus areas include:
Stage II
Stage I
Stage III
2Hodgkin's Lymphoma
Matthew J. Ehrhardt has run 1 trial for Hodgkin's Lymphoma. Some of their research focus areas include:
Stage II
Stage I
Stage III

Affiliated Hospitals

Image of trial facility.
St Jude Children's Research Hospital
Image of trial facility.
Saint Jude Children's Research Hospital

Clinical Trials Matthew J. Ehrhardt is currently running

Image of trial facility.

Chemotherapy + Radiotherapy

for Hodgkin's Lymphoma

This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC) (CAPDac) chemotherapy. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an adequate response (AR) after 2 cycles of therapy for all risk groups.
Recruiting1 award Phase 216 criteria

More about Matthew J. Ehrhardt

Clinical Trial Related6 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments Matthew J. Ehrhardt has experience with
  • Cyclophosphamide
  • Bendamustine
  • Bleomycin
  • Brentuximab Vedotin
  • Doxorubicin
  • DTIC
Breakdown of trials Matthew J. Ehrhardt has run
Lymphoma
Hodgkin's Lymphoma
B-Cell Lymphoma
Large B-Cell Lymphoma

Other Doctors you might be interested in

Hiroto Inaba, MD, PhDSt. Jude Children's Research Hospital
Giles Robinson, MDSt. Jude Children's Research Hospital
Sara M Federico, MDSaint Jude Children's Research Hospital

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew J. Ehrhardt specialize in?
Matthew J. Ehrhardt focuses on Lymphoma and Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage II patients, or patients who are Stage I.
Is Matthew J. Ehrhardt currently recruiting for clinical trials?
Yes, Matthew J. Ehrhardt is currently recruiting for 1 clinical trial in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Matthew J. Ehrhardt has studied deeply?
Yes, Matthew J. Ehrhardt has studied treatments such as Cyclophosphamide, Bendamustine, Bleomycin.
What is the best way to schedule an appointment with Matthew J. Ehrhardt?
Apply for one of the trials that Matthew J. Ehrhardt is conducting.
What is the office address of Matthew J. Ehrhardt?
The office of Matthew J. Ehrhardt is located at: St. Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the St. Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security